## A: Agilent Technologies, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 4.8% in lower entry zone (4.0-10.0%), top quartile (85th pct) cross-sectional ranking. Short-term MRS_5 (3.0%) confirms momentum alignment. Strong momentum (+7.3% 5-day acceleration). Outperforming sector by 2.5%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($141.56)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Why Agilent (A) Stock Is Up Today**
- Source: TradingView â€” Track All Markets | 20260107T080833 | Bullish | Relevance: 100%
- Agilent Technologies (A) stock jumped 2.8% after Evercore ISI upgraded the company to 'Outperform' and raised its price target to $160 from $155. This upgrade reflects increased confidence in Agilent's future performance. The stock's current performance shows a 7.2% gain since the start of the year, trading near its 52-week high.

**2. Why Agilent (A) Stock Is Up Today**
- Source: Finviz | 20260106T210801 | Bullish | Relevance: 100%
- Agilent Technologies (NYSE:A) shares rose after Evercore ISI upgraded the stock to 'Outperform' and increased its price target to $160.00. This upgrade highlights growing market optimism for the life sciences tools company, which has seen positive ratings from several financial firms. Despite the initial jump, shares cooled slightly, but the move signals market confidence in Agilent's prospects.

**3. Why Agilent (A) Shares Are Rising Today**
- Source: Bitget | 20260106T200824 | Bullish | Relevance: 100%
- Agilent Technologies (A) saw its stock price rise by 2.8% following an upgrade from Evercore ISI, which changed its rating from 'In-Line' to 'Outperform' and increased its price target to $160.00. This positive reassessment reflects growing confidence in Agilent, with its shares settling at $147.85 and trading near its 52-week peak. The article also provides historical context on the stock's volatility and past market reactions.

**4. The Truth About Agilent Technologies Inc: Quiet Lab Stock That Might Be Your Next Power Play**
- Source: AD HOC NEWS | 20260105T232946 | Bullish | Relevance: 100%
- Agilent Technologies Inc (A) is presented as a quiet yet powerful player in the lab technology sector, supporting pharma, biotech, and semiconductor industries. The article suggests that while it lacks the viral "hype" of AI or meme stocks, its "picks-and-shovels" business model, steady growth, and integral role in scientific research make it a compelling long-term investment. It is compared to competitors like Thermo Fisher Scientific, highlighting Agilent's focus on precision instruments and analytics.

**5. Gateway Investment Advisers LLC Decreases Holdings in Agilent Technologies, Inc. $A**
- Source: MarketBeat | 20260105T161010 | Somewhat-Bullish | Relevance: 100%
- Gateway Investment Advisers LLC significantly reduced its stake in Agilent Technologies (NYSE:A) by 58.7% in Q3, selling 98,173 shares and retaining 69,018 shares valued at approximately $8.86 million. Despite insider selling activity totaling around $2.47 million in the past 90 days, Wall Street analysts maintain a "Moderate Buy" rating with a consensus price target of $161.77. Agilent recently surpassed Q3 earnings and revenue expectations, issued positive FY26 EPS guidance, and increased its quarterly dividend.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Evercore ISI Gr | $160 | $155 | +3% |
| 2025-12-15 | Barclays | $165 | $165 | 0% |
| 2025-12-09 | Goldman Sachs | $170 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Evercore ISI Gr | up | Outperform |
| 2025-12-15 | Barclays | up | Overweight |
| 2025-12-09 | Goldman Sachs | init | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 10 ($1.37M) |
| Sells | 18 ($1.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (+0.1%)
- Blackrock Inc.: 9.2% (+1.0%)
- Massachusetts Financ: 4.4% (-6.0%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.3% (+4.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +7.3% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.12 elevated, pricing in significant growth expectations. Forward P/E 22.5x stretched relative to 10% growth. Quality metrics strong (ROE 21%, margin 19%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $41.9B |
| Beta | 1.29 |
| 52W Range | $96.43 - $160.27 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.12 |
| Forward P/E | 22.5 |
| Current P/E | 24.8 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -2.5% to 4.8% (+7.3% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 85th percentile. MRS_5 at 3.0% confirms short-term momentum alignment. AM_20 at 5.8% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.23), confirming momentum. OFD pattern: +DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.78% (CS: 86) | Strong |
| RSI_14 | 63.5 | Neutral |
| MACD Histogram | 1.23 | Bullish |
| vs SMA20 | 1.056x | Above |
| vs SMA50 | 1.022x | Above |
| vs SMA200 | 1.178x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $147.78
- **Stop Loss:** $141.56 (4.2% risk)
- **Target:** $157.11 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 192
- **Position Value:** $28,373.76
- **Portfolio %:** 28.37%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk appetite. VIX at 15.38 sits in the normal range (18th percentile of 52-week) with modest upward drift, while yield curve remains positively sloped (+62bps 10Y-3M) supporting risk assets. Breadth at 59.5% shows healthy participation, though elevated put/call ratio (1.12) suggests some hedging activity. FOMC 20 days out provides runway for current conditions to persist.*

### Earnings

**Next:** 2026-02-25 (Est: $1.37)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.58 | $1.59 | +0.4% |
| 2025Q3 | $1.37 | $1.37 | +0.2% |
| 2025Q2 | $1.26 | $1.31 | +3.6% |
| 2025Q1 | $1.27 | $1.31 | +3.0% |

---
*RULE-based L3 | 2026-01-08 08:02 | MRS_20*